Clinical Trial Update: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC [Phase 3]

View source ↗

Summary

Phase 3 global trial assessing durvalumab plus domvanalimab after concurrent chemoradiation in stage III unresectable non-small cell lung cancer; study actively…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Domvanalimab (domvanalimab)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING